Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2009-11-27

AUTHORS

Steven C. Goldstein , Selina Luger

ABSTRACT

The number of reduced-intensity conditioning (RIC)/nonmyeloablative transplants (NMT) has risen steadily over the last 10 years, now comprising approximately 30% of all allogeneic transplants performed annually [1]. Despite the rapid rise in its application, we have much to learn in terms of optimizing conditioning regimens, GvHD prophylaxis, identifying appropriate patient cohorts, and disease states, thus balancing the critical endpoints of chimerism, GvHD, relapse, and toxicity for the optimal utilization of this strategy.Building on the landmark work by Storb et al. [2, 3] in the canine model, the paradigm requiring myeloablation of the host immunohematopoietic system for successful long-term donor hematopoietic engraftment, has been replaced by the view that nonmyeloablative allogeneic transplantation is at its essence, the truest form of cellular immunotherapy. At its inception approximately a decade ago, the initial goal was to offer potentially curative treatment to patients previously excluded from consideration for standard allotransplantation secondary to age and/or other comorbid conditions. Early papers in RIC/NMT focused on the critical goals of establishing donor hematopoiesis with low early treatment-related mortality; notably absent was the demonstration of long-term disease control [4]. Whether NMT/RIC can improve on the disease outcomes of standard transplantation as opposed to simply broadening the pool of potential candidates for allotransplantation remains an area of active investigation. More... »

PAGES

441-458

Book

TITLE

Allogeneic Stem Cell Transplantation

ISBN

978-1-934115-33-6
978-1-59745-478-0

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_25

DOI

http://dx.doi.org/10.1007/978-1-59745-478-0_25

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049124684


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412713.2", 
          "name": [
            "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldstein", 
        "givenName": "Steven C.", 
        "id": "sg:person.016115210252.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412713.2", 
          "name": [
            "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luger", 
        "givenName": "Selina", 
        "id": "sg:person.012415664717.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012415664717.68"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-11-27", 
    "datePublishedReg": "2009-11-27", 
    "description": "The number of reduced-intensity conditioning (RIC)/nonmyeloablative transplants (NMT) has risen steadily over the last 10 years, now comprising approximately 30% of all allogeneic transplants performed annually [1]. Despite the rapid rise in its application, we have much to learn in terms of optimizing conditioning regimens, GvHD prophylaxis, identifying appropriate patient cohorts, and disease states, thus balancing the critical endpoints of chimerism, GvHD, relapse, and toxicity for the optimal utilization of this strategy.Building on the landmark work by Storb et al. [2, 3] in the canine model, the paradigm requiring myeloablation of the host immunohematopoietic system for successful long-term donor hematopoietic engraftment, has been replaced by the view that nonmyeloablative allogeneic transplantation is at its essence, the truest form of cellular immunotherapy. At its inception approximately a decade ago, the initial goal was to offer potentially curative treatment to patients previously excluded from consideration for standard allotransplantation secondary to age and/or other comorbid conditions. Early papers in RIC/NMT focused on the critical goals of establishing donor hematopoiesis with low early treatment-related mortality; notably absent was the demonstration of long-term disease control [4]. Whether NMT/RIC can improve on the disease outcomes of standard transplantation as opposed to simply broadening the pool of potential candidates for allotransplantation remains an area of active investigation.", 
    "editor": [
      {
        "familyName": "Lazarus", 
        "givenName": "Hillard M.", 
        "type": "Person"
      }, 
      {
        "familyName": "Laughlin", 
        "givenName": "Mary J.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-59745-478-0_25", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-934115-33-6", 
        "978-1-59745-478-0"
      ], 
      "name": "Allogeneic Stem Cell Transplantation", 
      "type": "Book"
    }, 
    "keywords": [
      "reduced-intensity conditioning", 
      "early treatment-related mortality", 
      "long-term disease control", 
      "treatment-related mortality", 
      "allogeneic stem cell transplantation", 
      "appropriate patient cohorts", 
      "donor hematopoietic engraftment", 
      "nonmyeloablative allogeneic transplantation", 
      "novel preparative regimens", 
      "stem cell transplantation", 
      "GVHD prophylaxis", 
      "preparative regimens", 
      "allogeneic transplants", 
      "conditioning regimens", 
      "donor hematopoiesis", 
      "allogeneic transplantation", 
      "cellular immunotherapy", 
      "curative treatment", 
      "comorbid conditions", 
      "cell transplantation", 
      "patient cohort", 
      "disease outcome", 
      "hematopoietic engraftment", 
      "canine model", 
      "immunohematopoietic system", 
      "standard transplantation", 
      "transplantation", 
      "Disease Control", 
      "disease states", 
      "active investigation", 
      "regimens", 
      "allotransplantation", 
      "transplant", 
      "GVHD", 
      "prophylaxis", 
      "relapse", 
      "immunotherapy", 
      "patients", 
      "myeloablation", 
      "engraftment", 
      "cohort", 
      "chimerism", 
      "mortality", 
      "rapid rise", 
      "endpoints", 
      "outcomes", 
      "treatment", 
      "critical goal", 
      "initial goal", 
      "toxicity", 
      "potential candidate", 
      "hematopoiesis", 
      "years", 
      "controversy", 
      "control", 
      "conditioning", 
      "inception", 
      "optimal utilization", 
      "goal", 
      "use", 
      "candidates", 
      "demonstration", 
      "pool", 
      "strategies", 
      "NMT", 
      "number", 
      "critical endpoint", 
      "utilization", 
      "investigation", 
      "rise", 
      "decades", 
      "area", 
      "true form", 
      "landmark work", 
      "paradigm", 
      "consideration", 
      "conditions", 
      "form", 
      "et al", 
      "model", 
      "view", 
      "state", 
      "terms", 
      "system", 
      "concept", 
      "work", 
      "applications", 
      "al", 
      "essence", 
      "earlier paper", 
      "paper", 
      "Storb et al", 
      "host immunohematopoietic system", 
      "successful long-term donor hematopoietic engraftment", 
      "long-term donor hematopoietic engraftment", 
      "standard allotransplantation", 
      "RIC/NMT", 
      "low early treatment-related mortality", 
      "NMT/RIC"
    ], 
    "name": "Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation", 
    "pagination": "441-458", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049124684"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-59745-478-0_25"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-59745-478-0_25", 
      "https://app.dimensions.ai/details/publication/pub.1049124684"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_49.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-59745-478-0_25"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_25'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_25'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_25'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_25'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      23 PREDICATES      124 URIs      117 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-59745-478-0_25 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N28b76f7c2af5470fbfdc759a428b1663
4 schema:datePublished 2009-11-27
5 schema:datePublishedReg 2009-11-27
6 schema:description The number of reduced-intensity conditioning (RIC)/nonmyeloablative transplants (NMT) has risen steadily over the last 10 years, now comprising approximately 30% of all allogeneic transplants performed annually [1]. Despite the rapid rise in its application, we have much to learn in terms of optimizing conditioning regimens, GvHD prophylaxis, identifying appropriate patient cohorts, and disease states, thus balancing the critical endpoints of chimerism, GvHD, relapse, and toxicity for the optimal utilization of this strategy.Building on the landmark work by Storb et al. [2, 3] in the canine model, the paradigm requiring myeloablation of the host immunohematopoietic system for successful long-term donor hematopoietic engraftment, has been replaced by the view that nonmyeloablative allogeneic transplantation is at its essence, the truest form of cellular immunotherapy. At its inception approximately a decade ago, the initial goal was to offer potentially curative treatment to patients previously excluded from consideration for standard allotransplantation secondary to age and/or other comorbid conditions. Early papers in RIC/NMT focused on the critical goals of establishing donor hematopoiesis with low early treatment-related mortality; notably absent was the demonstration of long-term disease control [4]. Whether NMT/RIC can improve on the disease outcomes of standard transplantation as opposed to simply broadening the pool of potential candidates for allotransplantation remains an area of active investigation.
7 schema:editor N61fa605096664ce781c038acfb9adcce
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N0a9eedd466a94f3f899c972b94558395
12 schema:keywords Disease Control
13 GVHD
14 GVHD prophylaxis
15 NMT
16 NMT/RIC
17 RIC/NMT
18 Storb et al
19 active investigation
20 al
21 allogeneic stem cell transplantation
22 allogeneic transplantation
23 allogeneic transplants
24 allotransplantation
25 applications
26 appropriate patient cohorts
27 area
28 candidates
29 canine model
30 cell transplantation
31 cellular immunotherapy
32 chimerism
33 cohort
34 comorbid conditions
35 concept
36 conditioning
37 conditioning regimens
38 conditions
39 consideration
40 control
41 controversy
42 critical endpoint
43 critical goal
44 curative treatment
45 decades
46 demonstration
47 disease outcome
48 disease states
49 donor hematopoiesis
50 donor hematopoietic engraftment
51 earlier paper
52 early treatment-related mortality
53 endpoints
54 engraftment
55 essence
56 et al
57 form
58 goal
59 hematopoiesis
60 hematopoietic engraftment
61 host immunohematopoietic system
62 immunohematopoietic system
63 immunotherapy
64 inception
65 initial goal
66 investigation
67 landmark work
68 long-term disease control
69 long-term donor hematopoietic engraftment
70 low early treatment-related mortality
71 model
72 mortality
73 myeloablation
74 nonmyeloablative allogeneic transplantation
75 novel preparative regimens
76 number
77 optimal utilization
78 outcomes
79 paper
80 paradigm
81 patient cohort
82 patients
83 pool
84 potential candidate
85 preparative regimens
86 prophylaxis
87 rapid rise
88 reduced-intensity conditioning
89 regimens
90 relapse
91 rise
92 standard allotransplantation
93 standard transplantation
94 state
95 stem cell transplantation
96 strategies
97 successful long-term donor hematopoietic engraftment
98 system
99 terms
100 toxicity
101 transplant
102 transplantation
103 treatment
104 treatment-related mortality
105 true form
106 use
107 utilization
108 view
109 work
110 years
111 schema:name Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation
112 schema:pagination 441-458
113 schema:productId N32fe45935f6e4b97a17140dfa35ca50b
114 N4250e4d457e14619b1166016a79b12cd
115 schema:publisher N773ff62a2751418681a54256b5772964
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049124684
117 https://doi.org/10.1007/978-1-59745-478-0_25
118 schema:sdDatePublished 2022-01-01T19:26
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher Nb528421952e948bc878a9f8ee18ca579
121 schema:url https://doi.org/10.1007/978-1-59745-478-0_25
122 sgo:license sg:explorer/license/
123 sgo:sdDataset chapters
124 rdf:type schema:Chapter
125 N0a9eedd466a94f3f899c972b94558395 schema:isbn 978-1-59745-478-0
126 978-1-934115-33-6
127 schema:name Allogeneic Stem Cell Transplantation
128 rdf:type schema:Book
129 N28b76f7c2af5470fbfdc759a428b1663 rdf:first sg:person.016115210252.03
130 rdf:rest N83a4daa33c9845bfb65a6648b056027a
131 N323bf2dad47748708529b4ff90fd95c9 schema:familyName Laughlin
132 schema:givenName Mary J.
133 rdf:type schema:Person
134 N32fe45935f6e4b97a17140dfa35ca50b schema:name doi
135 schema:value 10.1007/978-1-59745-478-0_25
136 rdf:type schema:PropertyValue
137 N4250e4d457e14619b1166016a79b12cd schema:name dimensions_id
138 schema:value pub.1049124684
139 rdf:type schema:PropertyValue
140 N61fa605096664ce781c038acfb9adcce rdf:first Nc918822efb3b4619b8cac6bb02f8a15f
141 rdf:rest Nb9693dc57a384073ac51dcdb698ef495
142 N773ff62a2751418681a54256b5772964 schema:name Springer Nature
143 rdf:type schema:Organisation
144 N83a4daa33c9845bfb65a6648b056027a rdf:first sg:person.012415664717.68
145 rdf:rest rdf:nil
146 Nb528421952e948bc878a9f8ee18ca579 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Nb9693dc57a384073ac51dcdb698ef495 rdf:first N323bf2dad47748708529b4ff90fd95c9
149 rdf:rest rdf:nil
150 Nc918822efb3b4619b8cac6bb02f8a15f schema:familyName Lazarus
151 schema:givenName Hillard M.
152 rdf:type schema:Person
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:person.012415664717.68 schema:affiliation grid-institutes:grid.412713.2
160 schema:familyName Luger
161 schema:givenName Selina
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012415664717.68
163 rdf:type schema:Person
164 sg:person.016115210252.03 schema:affiliation grid-institutes:grid.412713.2
165 schema:familyName Goldstein
166 schema:givenName Steven C.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03
168 rdf:type schema:Person
169 grid-institutes:grid.412713.2 schema:alternateName Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA
170 schema:name Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...